Interleukin-2 receptor pathway via Cytokine-inducible SH2-containing protein (IL-2R pathway via CISH)

The Interleukin-2 (IL-2) receptor pathway via Cytokine-inducible SH2-containing protein (CISH) is a critical regulatory circuit in the immune system that controls the magnitude and duration of T-cell and Natural Killer (NK) cell activation. CISH, the first identified member of the Suppressor of Cytokine Signaling (SOCS) family, acts as an intracellular checkpoint by binding to phosphorylated tyrosine residues on the IL-2 receptor beta subunit (CD122) and JAK1, thereby blocking STAT5 recruitment and promoting the proteasomal degradation of signaling components. In the context of oncology, CISH serves as a potent 'brake' on anti-tumor immunity; its genetic deletion or pharmacological inhibition has been shown to significantly enhance the effector function of NK cells and CD8+ T-cells against various malignancies. Conversely, dysregulation of this pathway is implicated in susceptibility to infectious diseases and the development of autoimmune conditions. Therapeutic strategies targeting this pathway include IL-2 agonists to boost immunity, IL-2R antagonists for immunosuppression, and emerging CRISPR-based or small-molecule approaches to silence CISH for enhanced adoptive cell therapies.

Other names

CISH-mediated IL-2 signaling regulationCIS-mediated IL-2 receptor inhibitionCytokine-inducible SH2-containing protein pathwaySOCS family regulation of IL-2RInterleukin-2 receptor pathway via CIS

Drugs targeting this pathway typically act as IL-2 receptor agonists to stimulate immune response or antagonists to suppress it; experimental CISH inhibitors function by removing the intracellular 'brake' on IL-2 signaling to enhance the anti-tumor activity of T-cells and NK cells.